Portugal Approves Reimbursement for Akeega in BRCA-Mutated Prostate Cancer

The Portuguese health technology assessment authority has finalized niraparib abiraterone reimbursement in Portugal for the fixed-dose combination of niraparib and abiraterone acetate plus prednisone or prednisolone in adults with BRCA-mutated metastatic castration-resistant prostate cancer when chemotherapy is not indicated.

Niraparib Abiraterone Reimbursement Portugal Decision

This outcome followed recognition of non-quantifiable added therapeutic value versus abiraterone monotherapy, although indirect comparisons did not demonstrate superiority over enzalutamide. Initial economic modeling found the regimen exceeded cost-effectiveness thresholds from the national health service perspective. Price reductions achieved through confidential negotiation ultimately enabled hospital-use approval under a contractual framework. The decision aligns acquisition costs with observed radiographic progression-free survival gains of 8.65 months and a 45 percent risk reduction, alongside a 44 percent reduction in time to symptomatic progression.

Clinical Evidence from Phase 3 BRCA Subgroup

Data originated from the prespecified BRCA-mutated cohort of a multicenter phase 3 placebo-controlled trial. Investigators applied parametric survival curves within a three-state partitioned survival model projecting 40 years with weekly cycles and half-cycle correction. Portuguese EQ-5D-5L tariffs informed utility values, while oncology and urology specialists validated resource use against official national cost databases. Overall survival differences remained statistically nonsignificant after crossover adjustment for subsequent PARP inhibitor therapy. Grade 3 or higher adverse events, discontinuations, and fatal events occurred more frequently in the combination arm, yet patient-reported quality-of-life scores showed no meaningful between-group differences.

Ad

Economic Viability and Policy Adjustments

The resulting incremental cost-effectiveness ratio prompted the expert committee to require substantial price concessions before recommending niraparib abiraterone reimbursement Portugal. Health authorities demonstrated willingness to fund targeted regimens in molecularly defined populations once negotiated prices matched demonstrated progression and symptom benefits, even without confirmed survival gains. Confidential contractual arrangements proved essential in bridging trial-derived value and national willingness-to-pay limits for precision oncology products. Future submissions will likely benefit from early pricing engagement to shorten negotiation timelines while preserving rigorous evidence standards for both efficacy and safety.

Further details appear in the Akeega assessment report, which outlines the methodological and economic parameters supporting the final positive recommendation. This approach highlights how Portugal balances innovation access with fiscal responsibility in oncology.